The overall purpose of this proposal is to develop predictive biomarkers of treatment outcome in kidney transplant rejection, specifically in T-cell mediated rejection (TCMR), as the response to treatment can be variable, is currently not predictable by clinical diagnostics nor understood from a mechanistic sense, and even partial treatment failure is associated with shortened graft longevity. In each aim, we make use of residual diagnostic biopsy samples with paired richly-detailed clinical data and timelines including treatments, graft functional responses and outcomes. In this manner, we track along the clinical timeline of TCMR, with each aim addressing an unsolved clinical problem in the field. Through the same approach, experimental data from this unique ?model system? of tissue inflammation studied over time provides a rich discovery set for understanding tissue-resident T cell behavior in the human kidney.
Aim 1 looks at the whole transcriptome profiles of initial acute episodes of TCMR prior to treatment, to identify a gene expression signature predictive of resistance/sensitivity to standard therapies for rejection. When treatment fails, grafts frequently contain residual T cell infiltrates, but the causal connection between these cells and long- term outcome is unclear. For example, residual infiltrates may represent (i) contracting/egressing populations of T cells effectively treated, (ii) newly recruited T cells mounting a fresh rejection response where repeat therapy may be prudent, or (iii) scant memory T cells with established tissue posts and capable of inciting repeat inflammation. Therefore, in Aim 2, we focus on post-treatment biopsies of treatment failure, characterizing multiple spatio-phenotypic aspects of the T cell infiltrate by high dimensional immunofluorescence microscopy with digital image processing and quantitative spatial analysis, to determine which functional phenotypic T cell subsets in which specific tissue niches, correlate with poor graft outcomes. These complementary but independent aims will be achieved through established cross-disciplinary collaborations and with partial industry support.

Public Health Relevance

Kidney transplantation is life saving and compared to dialysis improves patient quality of life and decreases healthcare costs over time, but graft longevity is compromised by immunologic rejection and inadequate immunosuppression. Timely appropriate therapy for rejection can preserve graft longevity, but biomarkers to predict response to therapy are lacking, leading some centers to over-treat, putting patients at risk of infection and malignancy, while clinical protocols at other centers may under-treat, putting patients at risk of accelerated graft decline. Therefore, development of tests to guide appropriate selection of therapy for rejection would be clinically useful, and discovery-based platforms for biomarker identification have the potential to yield not only clinically useful tests but also to reveal biologic mechanisms of treatment resistance and potential new targets for therapy.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Transplantation, Tolerance, and Tumor Immunology Study Section (TTT)
Program Officer
Robien, Mark Andrew
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code